Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27e1ea5f65e8f958e48f1a9d53fdbb45 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-852 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-86 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c985340165377d04ab5b832f73e14085 |
publicationDate |
2020-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020163802-A1 |
titleOfInvention |
Cancer specific frameshift vaccines |
abstract |
A method of producing a vaccine for a cancer and/or tumor and stage of interest is disclosed. The method includes identifying a first population of peptides that are immunoreactive with a set of biological samples obtained from a set of test subjects that have been identified as having the cancer and/or tumor of interest, and preparing a cancer vaccine composition for the cancer of interest, wherein the cancer vaccine composition comprises a second population of peptides comprising one or more peptides in the first population or a nucleic acid sequence encoding the one or more peptides, thereby producing the vaccine for the cancer and/or tumor of interest. Also disclosed are vaccine compositions and methods of use thereof. |
priorityDate |
2019-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |